InnovaRadi’s R&D system is guided by scientific and clinical value, focusing on unmet clinical needs. Our targeted alpha therapy (TAT) programs are expected to achieve efficient cancer cell eradication through precise targeting and local energy deposition, will provide patients with a brand-new treatment pathway.

We are actively advancing a portfolio of innovative products covering solid tumor indications such as neuroblastoma, and pushing multiple programs into the clinical stage.